文献速递神经核医学肿瘤 PET/CT

脑18F-FDG PET/CT代谢作为免疫检查点阻断癌症治疗后中枢神经系统毒性的诊断标志

Cerebral 18F-FDG PET/CT Metabolism as Diagnostic Signature for Central Nervous System Toxicity After Immune Checkpoint Blockade Cancer Treatment.
PubMed 文献 · J Nucl Med · 2024-07-01

多中心观察性研究分析免疫检查点抑制剂治疗癌症患者脑部18F-FDG PET/CT区域代谢变化,发现中枢神经系统毒性患者SUVmean变化高于无毒性患者但低于中枢神经系统感染患者,治疗开始后5-6周早期SUVmean变化可预测后续中枢神经系统毒性发生。

要点

  • 中枢神经系统毒性患者脑区域SUVmean变化高于无毒性患者,但低于中枢神经系统感染患者。
  • 中枢神经系统毒性患者与无毒性患者区分AUC为0.83(95%CI 0.78-0.88)。
  • 验证队列中治疗开始后5-6周SUVmean变化预测后续中枢神经系统毒性AUC为0.86(95%CI 0.79-0.94)。

核心结论

  • 中枢神经系统毒性临床发作期间及之前可检测到脑区域高代谢,中枢神经系统毒性可能是不同于脑感染的独立病理实体,区域SUV差异可能转化为基于中等区分准确度的早期诊断工具。

研究设计与样本

  • 多中心观察性研究,2020年1月至2022年2月分析接受免疫检查点抑制剂治疗的癌症患者中枢神经系统毒性发作前及发作时的区域代谢变化。
  • 6,395例接受免疫检查点抑制剂治疗的患者中,2,387例接受了预后性18F-FDG PET/CT检查,125例扫描患者发生中枢神经系统毒性(中位时间9周,四分位距2-23周)。
  • 采用1:1倾向评分匹配比较中枢神经系统毒性患者与中枢神经系统感染患者及无中枢神经系统毒性或感染患者的双侧脑叶区域SUVmean。
  • 验证队列于2022年2月至2023年7月招募患者,免疫检查点抑制剂开始后随访24周,评估治疗开始后5-6周区域SUVmean早期变化预测后续中枢神经系统毒性发作的能力,验证队列共2,878例患者。

主要发现

  • 中枢神经系统毒性患者区域18F-FDG PET/CT SUVmean变化高于无中枢神经系统毒性患者(117对患者),但低于中枢神经系统感染患者(50对)。
  • 中枢神经系统毒性患者与无中枢神经系统毒性患者区分分析AUC为0.83(95%CI 0.78-0.88),中枢神经系统毒性患者与中枢神经系统感染患者区分AUC为0.80(95%CI 0.72-0.89)。
  • 中枢神经系统毒性发作前SUVmean变化也高于无中枢神经系统毒性患者(60对;AUC 0.74;95%CI 0.66-0.83)。
  • 验证队列2,878例患者中,发作前SUVmean变化预测后续中枢神经系统毒性发生的AUC为0.86(95%CI 0.79-0.94)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our aim was to investigate probable biomarkers specific to immune-related central nervous system toxicity (CNST) in cancer patients treated with immune checkpoint inhibitors (ICI) by analysis of 18F-FDG PET/CT images. Methods: Cancer patients receiving ICI treatment were enrolled in a multicenter observational study that analyzed regional metabolic changes before and during CNST onset from January 2020 to February 2022. In 1:1 propensity score-matched pairs, the regional SUVmean of each bilateral brain lobe of CNST patients (CNST+) was compared with that of patients who had central nervous system infections (CNSIs) and patients without CNST or CNSI (CNST-). In a validation cohort, patients were recruited from February 2022 to July 2023 and followed up for 24 wk after the start of ICI. Early changes in regional SUVmean at 5-6 wk after therapy initiation were evaluated for ability to predict later CNST onset. Results: Of 6,395 ICI-treated patients, 2,387 underwent prognostic 18F-FDG PET/CT and 125 of the scanned patients had CNST (median time from ICI treatment to onset, 9 wk; quartile range, 2-23 wk). Regional 18F-FDG PET/CT SUVmean changes were higher in CNST+ than in CNST- patients (117 patient pairs) but were lower than in CNSI patients (50 pairs). Differentiating analysis reached an area under the curve (AUC) of 0.83 (95% CI, 0.78-0.88) for CNST+ versus CNST- and of 0.80 (95% CI, 0.72-0.89) for CNST+ versus CNSI. Changes in SUVmean were also higher before CNST onset than for CNST- (60 pairs; AUC, 0.74; 95% CI, 0.66-0.83). In a validation cohort of 2,878 patients, preonset changes in SUVmean reached an AUC of 0.86 (95% CI, 0.79-0.94) in predicting later CNST incidence. Conclusion: Brain regional hypermetabolism could be detected during and before CNST clinical onset. CNST may be a distinct pathologic entity versus brain infections defined by 18F-FDG PET/CT brain scans. Regional SUV differences may be translated into early diagnostic tools based on moderate differentiating accuracy in our study.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ma Y, Zeng J, Ding F, et al. Cerebral 18F-FDG PET/CT Metabolism as Diagnostic Signature for Central Nervous System Toxicity After Immune Checkpoint Blockade Cancer Treatment. J Nucl Med. 2024. PMID: 38697671. doi:10.2967/jnumed.123.267025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。